New Enterprise Associates

New Enterprise Associates (NEA) is a prominent venture capital firm established in 1977, headquartered in Menlo Park, California, with additional offices in the U.S., India, and China. NEA specializes in investing in technology and healthcare sectors, with a focus on enterprise, consumer, fintech, life sciences, and digital health companies. The firm engages with entrepreneurs at various stages of business development, providing support from initial funding to public offerings. NEA invests globally, with a significant presence in Asia, including China and India, as well as the United States. The firm typically invests between $0.05 million and $20 million per deal.

Michael Albert

Associate

Kate Barrett

Partner, Communications

Ron Bernal

Venture Partner

Ann Bordetsky

Partner

Zak Burns

Associate

James Buxton MD

Principal

Carmen Chang

Partner and Head of Asia

Philip Chopin

Managing Director, NEA UK

Brandon Christie

VC Principal

Pamela Clark

General Partner

Vanessa Deng

Associate

Chris Doppman

Managing Director, LP Relations

Jonathan Golden

Partner

Scott Gottlieb MD

Partner

Jay Graf

Venture Partner

Aaron Jacobson

Partner

Arjun Jain

Senior Associate

James Kaplan

Associate

Nick Kline

Partner, LP Relations

Danielle Lay

Partner

Tiffany Le

Principal

Michael Li

Principal

Tiffany Luck

Partner

Ed Mathers

Partner and Board Member

Matthew McAviney

Partner

Michael O'Dell

Venture Partner

Kemi Odusan

Senior Associate

Jess Ou

Principal

Greg Papadopoulos

Venture Partner

Michele Park

Partner

Eileen Qian

Associate

Tim Schaller

CFO

Alex Sharata

Partner

George Stamas

Venture Partner

Brad Thawley

Partner, Limited Partner Relations

Blake Wu

Partner

Lulu Xu

Principal

Edison Zhang

Associate

J.C. Lopez

Principal on NEA's Healthcare Team

Arno Penzias Ph.D

Venture Partner

2244 past transactions

Chaos

Series C in 2025
Chaos Industries is a technology company dedicated to developing advanced solutions for defense and critical industries. The company specializes in detection and radar services, leveraging its innovative Coherent Distributed Networks (CDN) to improve sensing, detection, and communication capabilities across multiple platforms. By focusing on the needs of defense clients, Chaos Industries enhances product development and ensures the delivery of high-quality services tailored to the demands of the sector.

Veza

Series D in 2025
Veza is the data security platform that helps users use and share their data safely. It makes it easy to understand, manage, and control who can and should take what action on what data. It organizes authorization metadata across identity providers, data systems, cloud service providers, and applications, all to address the toughest data security challenges of the modern era. The company is funded by top-tier investors including Accel, Bain Capital, Ballistic Ventures, Blackstone, GV, Norwest Venture Partners, and True Ventures.

Glacier

Series A in 2025
Glacier, founded in 2019 and headquartered in San Francisco, California, specializes in the development of advanced recycling robots. The company has created the first affordable, high-performing, and space-efficient AI-enabled robots designed to transform the operations of recycling facilities. By utilizing artificial intelligence-powered sensors and robotics, Glacier's technology automates the sorting of recyclable materials, allowing facilities to enhance operational efficiency, improve sorting accuracy, and increase overall profitability. Through its innovative approach, Glacier aims to revolutionize the recycling industry and promote more effective waste management practices.

Plaid

Venture Round in 2025
Plaid Inc. is a technology company that facilitates the connection between consumers' bank accounts and applications, aiming to democratize financial services through advanced technological solutions. Founded in 2012 and headquartered in San Francisco, it provides a comprehensive suite of APIs that enable developers to create financial products connecting users with traditional financial institutions. Plaid's offerings include tools for accessing transaction history and balance data, authenticating bank accounts for payments, verifying identities, and confirming real-time account balances and income. These products support various applications in personal finances, consumer payments, lending, banking, and business finance. With a focus on enhancing both consumer experiences and developer capabilities, Plaid serves a diverse range of clients, including Fortune 50 companies, positioning itself as a vital infrastructure provider in the digital financial landscape.

Aetherflux

Series A in 2025
Aetherflux is an aerospace company focused on providing renewable energy solutions to households, businesses, and military operations worldwide. The company has developed an innovative design for space-based solar power, which entails a constellation of small satellites that harness sunlight, convert it into electricity, and wirelessly transmit the power to ground stations. This technology aims to deliver reliable energy distribution while minimizing environmental impact, positioning Aetherflux at the forefront of the renewable energy sector.

Vori Health

Series B in 2025
Vori Health is a healthcare organization that specializes in the treatment of musculoskeletal conditions through an innovative care delivery model. Established in 2020 and headquartered in New York, Vori Health provides a comprehensive range of services, including integrated medical and rehabilitation care, physical therapy, prescription management, imaging and lab ordering, health coaching, nutritional guidance, and community support. The company employs a virtual-first approach, connecting patients with a trained care team that includes board-certified, non-operative physical medicine physicians, health coach navigators, and physical therapists. This collaborative model ensures thorough initial assessments and coordinated care, aimed at guiding patients through their wellness journeys, particularly in addressing issues related to the back, neck, and joints.

Ceramic.ai

Seed Round in 2025
Ceramic.ai builds enterprise-grade infrastructure to optimize how companies train and deploy their AI models

Ceramic

Seed Round in 2025
Ceramic is an AI company that specializes in streamlining the process of training artificial intelligence models for businesses. Their platform optimizes data processing and supports long-context training across various cluster sizes, making AI model training faster and more cost-effective. This enables enterprises to efficiently build and fine-tune their own generative AI models.

Metronome

Series C in 2025
Metronome is a billing infrastructure company focused on supporting software companies in launching, iterating, and scaling their usage-based business models. The company offers metering and data mediation software that enhances billing capabilities, ensuring a robust data infrastructure and real-time architecture tailored for usage-based billing. Metronome emphasizes rapid deployment, flexibility, and user-friendliness, reducing the engineering demands typically associated with billing systems. This enables business and product teams to manage revenue and pricing effectively. Following initial platform integration, teams can quickly introduce new products and pricing options, streamline revenue workflows, and grant customers immediate access to their spending insights.

Cambium Carbon

Series A in 2025
Cambium Carbon is an early-stage social enterprise focused on addressing climate change through innovative reforestation and urban wood reuse initiatives. The company collaborates with cities and various public and private partners to salvage fallen city trees that would otherwise end up in landfills. By transforming this wood waste into valuable resources, Cambium Carbon establishes reforestation hubs that create a circular economy for urban forests. These hubs not only generate revenue to support tree planting and maintenance projects but also foster sustainable job creation and contribute to the development of resilient urban environments. Through its efforts, Cambium Carbon aims to implement systems-level natural climate solutions that benefit both the environment and local communities.

Abcuro

Series C in 2025
Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Established in 2015 and headquartered in Newton, Massachusetts, Abcuro specializes in creating therapeutic antibodies that target novel pathways in these diseases. The company employs advanced bioinformatics to analyze transcription data from human diseases, enabling them to identify new therapeutic targets within the immune system. By leveraging clinical insights and systematic target validation, Abcuro aims to develop immune-modulatory biotherapeutics that provide innovative treatment options for patients suffering from autoimmune disorders and cancer.

Moises

Series A in 2025
Moises is an audio technology company focused on enhancing music and audio processing through machine learning and data science. It provides a platform equipped with advanced artificial intelligence tools designed for musicians and producers. Key features of the platform include audio separation, pitch and beat detection, chord detection, a metronome, tempo changing, and mastering capabilities. These tools empower users to practice, study, teach, and play music, allowing for greater customization and editing of tracks. Moises aims to support creative processes by leveraging innovative technology tailored to the needs of the music community.

Instabase

Series D in 2025
Instabase, Inc. is a technology company based in San Francisco, California, founded in 2015. It specializes in developing a platform that automates document processing workflows and analyzes unstructured data. The platform integrates various capabilities, including optical character recognition, data classification and extraction, and natural language processing, allowing organizations across sectors such as insurance, finance, and healthcare to streamline operations and improve decision-making. Additionally, Instabase provides a developer kit that enables the creation of customized business applications, helping institutions embed artificial intelligence into their systems and processes. Through its innovative solutions, Instabase aims to address significant business challenges and facilitate transformational outcomes for its clients.

Synthesia

Series D in 2025
Synthesia Ltd. is a London-based company that specializes in artificial intelligence-driven video production. Founded in 2017, it offers a platform that transforms text into professional-quality videos, featuring customizable avatars and voiceovers in over 140 languages. This technology allows users to create, edit, and share videos efficiently, making it ideal for applications such as personalized advertising, corporate communications, training, and marketing. The platform's advanced capabilities include synchronizing lip movements with new dialogue tracks, facilitating the translation of video content into multiple languages. By enabling content creators to produce localized videos at scale, Synthesia aims to democratize video content creation and enhance communication across diverse audiences.

Tune Therapeutics

Series B in 2025
Tune Therapeutics is a biotechnology company focused on developing innovative cell and gene therapies. It employs an epigenetic programming platform to create novel therapeutic pathways, aiming to treat severe diseases without modifying the underlying DNA sequence.

Ouro Medicines

Series A in 2025
Ouroboros Medicines is a biotechnology company dedicated to immunology, focusing on treating chronic immune-mediated illnesses. It specializes in developing immune reset treatments, using a therapeutic platform that employs T cell engager antibodies to target and deplete specific pathogenic cells. This approach aims to provide extended remissions for patients, without the need for ongoing immunosuppression. The company's strength lies in its integration of scientific knowledge and proven track record in progressing cell-depleting treatments through clinical trials, supported by a robust pipeline.

Fire1

Venture Round in 2025
Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Orbis Medicines

Series A in 2025
Orbis Medicines is a biotechnology company focused on advancing drug discovery through its innovative macrocyclic chemistry and computational platform. The company specializes in high-throughput drug discovery, aiming to develop new therapeutics that can significantly improve patient outcomes. By leveraging its unique chemistry and advanced computational techniques, Orbis Medicines seeks to address challenging targets in areas with high unmet medical needs, thereby accelerating the process of bringing effective treatments to market.

NeueHealth

Acquisition in 2024
NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Courtyard.io

Venture Round in 2024
Courtyard.io is a platform that facilitates the conversion of physical collectibles into non-fungible tokens (NFTs), enabling secure and instantaneous ownership transfers without the need to physically move the items. By tokenizing collectibles, Courtyard.io enhances the liquidity of these assets and simplifies the authentication process for transactions within the collectibles market. The platform offers secure storage for physical items in vaults, creates three-dimensional representations of these assets, and mints them as NFTs on the blockchain. This innovative approach not only redefines ownership of physical goods but also fosters a community where collectors can showcase their collections in the metaverse.

Backflip AI

Series A in 2024
Backflip AI operates a platform that combines human creativity with 3D generative AI, enabling engineers and designers to work efficiently and produce highly realistic models. These models can be used in various applications, such as 3D printing, video game assets, renders, and digital media, as well as in the design of physical structures like buildings and automobiles. The company's technology aims to accelerate design processes and provide businesses with a competitive edge.

Senti Bio

Post in 2024
Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, a targeted cancer therapy using gene-engineered allogeneic CAR-NK cells designed to eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A for treating hepatocellular carcinoma.

Avenzo

Series A in 2024
Avenzo Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for oncology, specifically targeting underserved and rare cancers. The company operates a specialized platform that focuses on creating novel treatments aimed at genomically defined cancer types. By prioritizing targeted therapies, Avenzo Therapeutics seeks to advance cancer treatment options for patients who may not have access to effective solutions, thus addressing significant gaps in the current therapeutic landscape.

Fastino

Pre Seed Round in 2024
Fastino specializes in developing high-performance, task-optimized language models for enterprise AI developers. Their large language model (LLM) is designed to efficiently and accurately handle a range of data tasks, including structuring, summarization, planning, and sensitive information management. By offering near-instant inference, Fastino helps businesses enhance operational efficiency and process data at scale.

Sana

Series C in 2024
Sana Labs is a leader in applying artificial intelligence to enhance educational outcomes through personalized learning. The company collaborates with prominent organizations to develop its innovative learning platform, which leverages advanced machine learning techniques. This platform is designed to empower education companies and integrates seamlessly with various applications, allowing employees to access knowledge, communicate, and automate tasks effectively. By offering insights into team strengths, weaknesses, and progress, Sana enables institutions in sectors such as healthcare, finance, and pharmaceuticals to improve their workforce's performance and learning experiences. The interdisciplinary team at Sana comprises experts from diverse fields, contributing to its mission of transforming the future of education.

Pathos

Series C in 2024
Pathos is a company that focuses on enhancing the drug discovery process through its AI-enabled platform. This self-learning technology leverages big data and artificial intelligence to streamline the identification and validation of drug targets, ultimately establishing their clinical efficacy. By facilitating the exploration of novel concepts, Pathos aims to support drug developers in advancing innovative therapies. The platform is designed to manage the entire end-to-end process of designing and developing new therapeutics, thereby significantly reducing the time required for medication development.

Outrider

Series D in 2024
Outrider, Inc. is a software company specializing in the automation of logistics hubs through the use of electric, self-driving trucks. Founded in 2017 and based in Golden, Colorado, the company provides a software-as-a-service solution tailored for customer-owned fully and semi-autonomous freight and transportation fleets. Outrider's innovative system comprises web-based management software, autonomous driving controls for electric yard trucks, and essential site infrastructure. The autonomous vehicles are equipped with advanced sensor technology, including radar, lidar, and cameras, enabling them to automate various yard operations such as the movement of trailers, engaging and unhooking trailers, and monitoring trailer locations. The company's focus is on enhancing safety and efficiency for large enterprises by replacing hazardous and repetitive manual tasks with automated processes, thereby driving the adoption of sustainable freight transportation.

Genmo

Series A in 2024
Genmo is a technology company that develops an artificial intelligence platform for creative content generation. Its platform enables users to create high-quality videos, images, and 3D models using intuitive text and image prompts, leveraging advanced natural language processing technology. This allows video creators to generate custom visual media and produce cinematic video content with the assistance of AI.

Inventiva Pharma

Post in 2024
Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Firestorm

Series A in 2024
Firestorm is a company focused on developing modular open-source architecture tailored to meet the requirements of the Department of Defense, emphasizing the creation of low-cost and affordable solutions. It specializes in the manufacture of loitering munitions and mission-adaptable systems, designed to enhance aerial weaponry. Firestorm's systems are characterized by their modularity and precision payload delivery, equipping paratroopers with advanced aircraft suitable for modern, hyper-enabled battlefields.

Wispr Flow

Venture Round in 2024
Wispr Flow is a developer of a personal computing platform aimed at an artificial intelligence-first future, emphasizing neural interfaces. The company focuses on a human-centered approach that integrates advancements in neurotechnology, machine learning, and hardware systems. By doing so, Wispr Flow seeks to make cutting-edge technology accessible to a wider audience, allowing users to engage with technology in a more intuitive and natural manner.

858 Therapeutics

Series B in 2024
858 Therapeutics is a biotechnology company dedicated to the discovery of small molecule therapeutics aimed at treating cancers and other diseases, particularly those resistant to existing therapies. The company employs innovative strategies in areas such as synthetic lethality, innate immunity, and RNA modulation to develop its therapeutic candidates. Its lead program focuses on a PARG inhibitor, which is currently in early clinical development. By leveraging its platform to investigate the role of RNA modifying proteins in disease biology, 858 Therapeutics is generating a pipeline of targeted small molecules that address critical unmet medical needs in oncology and immunology.

DeltaStream

Series A in 2024
DeltaStream is a stream processing platform designed to assist businesses in processing and analyzing real-time streaming data. By leveraging the capabilities of Apache Flink, the platform offers serverless stream processing and a range of features such as data governance, real-time analytics, multi-platform capabilities, and monitoring. DeltaStream facilitates the creation of materialized views and supports third-party sharing, allowing organizations to efficiently manage their streaming analytics and database needs. With its emphasis on scalability and ease of use, the platform enables businesses to harness the full potential of their streaming data without the burden of infrastructure management.

World Labs

Venture Round in 2024
World Labs is a technology company that develops an artificial intelligence platform designed for humanlike processing of visual data. Focusing on spatial intelligence, its core service involves the creation of Large World Models (LWMs) that enable AI systems to perceive, generate, and interact with environments in three-dimensional space, both in virtual and real-world contexts. The company's innovative approach incorporates synthetic data to train its models, facilitating advanced computer vision technologies capable of reliably identifying objects. This capability positions World Labs as a key player in the burgeoning fields of augmented and virtual reality.

Second Front

Series C in 2024
Second Front Systems, Inc. is a technology company focused on enhancing government access to innovative, commercially developed technologies for national security applications. Founded in 2014 and headquartered in Arlington, Virginia, the company specializes in software solutions that facilitate the identification, assessment, and deployment of venture capital-backed technologies. Its primary product, Atlas Fulcrum, is a platform designed to streamline the discovery and engagement process for government users seeking advanced commercial technologies. Additionally, Second Front offers program management and system integration services to ensure the effective delivery of these technologies to military personnel. The company also operates the High Technology Council, an enterprise consortium that brings together key stakeholders to promote the application of venture-backed innovations in government-funded national security missions. With additional offices in Washington, D.C., and San Francisco, Second Front is positioned to transform how government entities access and utilize cutting-edge technology.

Agree.com

Pre Seed Round in 2024
Agree.com is the best solution for creating and managing contracts, streamlining negotiations, enhancing compliance, optimizing workflows, and converting more customers — all within one intuitive platform. View edits, track signatures, and get alerted on all upcoming key milestones. Include free, one-click e-signatures with identity verification on every agreement. Increase deal velocity and drive revenue impact with integrated payments.

Sakana AI

Series A in 2024
Sakana AI is a research-focused company dedicated to developing innovative foundation models inspired by nature. It specializes in creating an AI model capable of generating text, images, video, code, and multimedia, facilitating collaborative research and development in generative AI. The company's AI development process emphasizes evolution and collective intelligence.

Ceramic

Seed Round in 2024
Ceramic is an AI company that specializes in streamlining the process of training artificial intelligence models for businesses. Their platform optimizes data processing and supports long-context training across various cluster sizes, making AI model training faster and more cost-effective. This enables enterprises to efficiently build and fine-tune their own generative AI models.

PayZen

Series B in 2024
PayZen is a healthcare fintech startup focused on addressing the increasing burden of patient payment responsibilities. Founded in San Francisco in 2019 by Ariel Rosenthal, Itzik Cohen, and Tobias Mezger, the company offers a payment platform that allows patients to manage their out-of-pocket medical bills through convenient and transparent installment plans. By utilizing artificial intelligence-powered risk assessment tools, PayZen provides tailored payment options that enhance affordability for patients while improving cash flow for medical providers. This innovative approach enables healthcare providers to concentrate on delivering care rather than handling financial transactions, ultimately leading to better financial outcomes for both parties.

Moximed

Series D in 2024
Moximed, Inc. is a medical technology company based in Hayward, California, that focuses on developing innovative treatments for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain associated with medial compartment knee osteoarthritis, allowing patients to maintain high levels of activity. Additionally, Moximed has developed the MISHA Knee System, which provides an outpatient treatment option for individuals who have not responded to conventional therapies and are not suitable candidates for knee replacement surgery. By minimizing joint pain and providing dynamic load reduction, Moximed's implants aim to improve the standard of care and enhance the quality of life for patients, potentially delaying or avoiding the need for more invasive surgical interventions. Moximed has been operational since its incorporation in 2006, serving patients and medical professionals globally.

MBX Biosciences

Series C in 2024
MBX Biosciences, Inc. is a biotechnology company founded in 2018 and based in Carmel, Indiana. The company specializes in developing therapeutics for rare endocrine disorders, focusing on conditions that currently lack effective treatments. MBX Biosciences aims to discover, develop, and commercialize first-in-class therapies, particularly peptides designed to address endocrine genetic diseases that affect glandular hormone production and the body’s chemical messaging systems.

Augment Markets

Seed Round in 2024
Augment is a developer of a platform designed for confidential transactions and communications, specifically tailored for the private technology share market. The platform facilitates connections between buyers and sellers by providing an order book within a company's marketplace. Users can identify potential transaction partners, engage in secure communication, and finalize deals, streamlining the process for brokers, investors, and shareholders. This innovative approach allows participants in private market trades to efficiently manage their transactions while maintaining anonymity and confidentiality.

Global Predictions

Seed Round in 2024
Global Predictions is an innovative financial technology company founded by a team with deep expertise in artificial intelligence and finance. The company leverages its proprietary Economic Insights Engine to deliver a comprehensive suite of investing insights and financial advice. Global Predictions offers its services through an API and provides customized insights, making its fintech solutions accessible to millions. Its flagship product, PortfolioPilot.com, serves as a personal AI financial advisor for individuals, managing over $30 billion in assets. By combining advanced AI capabilities with financial expertise, Global Predictions aims to empower policymakers, corporations, and investors to navigate economic shifts and effectively manage their investment portfolios.

Clio

Series F in 2024
Clio is a Canadian company specializing in cloud-based practice management software for law firms. Its platform streamlines client management, billing, and communication, enabling lawyers to efficiently handle day-to-day tasks. Clio Ventures, an early-stage venture capital fund managed by Clio, invests in promising legal tech and SaaS startups, fostering innovation in the legal industry.

Magenta Medical

Venture Round in 2024
Magenta Medical Ltd. is a privately held company founded in 2012 and headquartered in Kadima, Israel. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its primary product line includes a temporary venous catheter-based therapy and a self-expanding heart pump designed to address key issues associated with acute heart failure, such as renal venous congestion. By enabling cardiac specialists to more effectively manage fluid and salt removal, Magenta Medical's solutions aim to improve patient outcomes while safeguarding kidney function.

Cardurion Pharmaceuticals

Series B in 2024
Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Amber Therapeutics

Series A in 2024
Amber Therapeutics is a biotechnology company that specializes in developing advanced bioelectrical therapies aimed at treating functional disorders of the peripheral nervous system. The company creates a bioelectronic platform that delivers closed-loop bioelectrical treatments, which can sense and adapt to the patient's needs while also providing stimulation. By focusing on conditions such as mixed urinary incontinence, Amber Therapeutics seeks to enhance clinical efficacy and patient outcomes through innovative approaches that emphasize the peripheral nervous system rather than the central nervous system. Its technology has the potential to significantly improve treatment methods and overall patient care in targeted disease areas.

Twelve Labs

Series A in 2024
Twelve Labs is a developer of a multimodal artificial intelligence platform that focuses on enhancing video understanding capabilities for businesses and developers. The platform enables users to analyze and interpret video content through various modalities, including visual and auditory data. It offers APIs for functions such as search, generation, and classification, allowing clients to create embeddings from videos to support a range of applications. Twelve Labs' technology is applicable across various industries, including technology, media, entertainment, and security, facilitating the development of intelligent video applications that can be deployed on any cloud and customized with specific data to meet user needs.

Faircado

Pre Seed Round in 2024
Faircado operates a sustainable shopping platform designed to enhance the circularity of produced goods by promoting second-hand purchases. The platform utilizes a smart algorithm that aggregates offers from various pre-owned marketplaces, allowing users to compare prices and sustainability scores of second-hand items across categories such as electronics and books. By centralizing these alternatives, Faircado enables consumers to make informed decisions that save time and money while supporting environmentally friendly shopping practices. The platform aims to reduce waste and foster a more sustainable approach to consumerism.

In-House Health

Seed Round in 2024
In-House Health is an AI-powered technical platform for modern nursing teams.

Zenas BioPharma

Series C in 2024
Zenas BioPharma is a clinical-stage biopharmaceutical company headquartered in Florida, USA, that specializes in developing immune-based therapies for patients. The company’s lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to target both CD19 and FcγRIIb, which are found in B cell lineages. This innovative approach aims to inhibit the activity of cells involved in various autoimmune diseases while preserving their presence, thus avoiding depletion. Through its focus on these advanced therapies, Zenas BioPharma seeks to address unmet medical needs in the treatment of autoimmune conditions.

SafeBase

Series B in 2024
SafeBase, Inc. is a San Francisco-based company founded in 2020 that specializes in cloud-based security software aimed at helping organizations establish and enhance their security programs. The company’s offerings include a smart trust center platform that facilitates the sharing of security posture and automates access to sensitive documents. SafeBase provides solutions such as SafeBase Inspected, which features a website badge linking to a custom security status page, as well as custom security checklists and continuous monitoring of security systems. Additionally, the software assists organizations in configuring security policies, thereby enabling them to implement robust security practices effectively.

Beehiiv

Series B in 2024
Beehiiv is a developer of an email newsletter platform that empowers creators to produce, monetize, and grow their newsletters. The platform enhances audience engagement through advanced customization and superior analytics, allowing users to effectively scale their web and email content. By offering a direct engagement model, Beehiiv enables publishers and advertisers to reduce reliance on lower-quality cookie-based data. Importantly, the company does not take a share of subscription revenue, providing a more lucrative financial model for creators. This approach facilitates the growth of custom newsletters and websites, supporting clients in expanding their reach and monetization efforts.

ARRIS

Venture Round in 2024
ARRIS specializes in advanced manufacturing technologies, particularly in the development of performance composites for various mass-market applications, including aerospace, automotive, and consumer products. The company's innovative additive molding technology enables the production of 3D-aligned continuous fiber thermoplastic composite parts at scale. This proprietary process allows for the precise alignment of continuous carbon fibers and the integration of electronic components and multifunctional materials into a single, topology-optimized structure. By combining these elements, ARRIS provides clients with access to advanced composite solutions that enhance product performance and efficiency.

Xaira Therapeutics

Venture Round in 2024
Xaira Therapeutics is a biotechnology company based in the San Francisco Bay Area that focuses on leveraging artificial intelligence to enhance drug discovery and development. The company integrates machine learning research, extensive biological and clinical data generation, and therapeutic product development to innovate how diseases are treated. By employing advanced AI methodologies, Xaira aims to transform the traditional drug development process, enabling the creation of more effective therapies. Through its multidisciplinary approach, the company seeks to advance understanding of biology and improve the overall efficiency of developing new treatments.

Perplexity

Venture Round in 2024
Perplexity is an artificial intelligence-based search engine platform that combines large language models with traditional search engines. It leverages natural language processing and generative AI technologies to deliver conversational responses to user queries, aiming to enhance the search experience beyond standard results. The platform is designed to facilitate the development of safe and beneficial artificial general intelligence, offering an open-source environment accessible to the public. This allows clients to acquire skills and knowledge in software development, positioning Perplexity as a bridge between conventional search capabilities and advanced AI-driven assistance.

Korro Bio

Post in 2024
Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

AI Squared

Series A in 2024
AI Squared helps large organizations bring AI to where work happens. We do this by leveraging our SaaS or on-prem platform which combines data sources with advanced AL/ML functionality and embeds intelligent insights into critical business applications. Trusted by the largest financial institutions, the most complicated supply chain logistics companies, and the US Department of Defense, we enable seamless collaboration between data science teams and business users, driving faster, more informed decision-making.

Avenzo

Series A in 2024
Avenzo Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative therapies for oncology, specifically targeting underserved and rare cancers. The company operates a specialized platform that focuses on creating novel treatments aimed at genomically defined cancer types. By prioritizing targeted therapies, Avenzo Therapeutics seeks to advance cancer treatment options for patients who may not have access to effective solutions, thus addressing significant gaps in the current therapeutic landscape.

Foundry

Series A in 2024
Foundry is a public cloud supported by an orchestration platform designed to simplify the utilization of AI computing resources. Foundry addresses fundamental economic and technical obstacles encountered in AI and deep learning. Current challenges faced by businesses, such as the notable GPU scarcity and inefficient use of computing capabilities, hinder their effective utilization of resources. Foundry employs pioneering approaches to overcome these hurdles, offering scalable GPU instances with unparalleled price-performance ratios.

Wonder

Venture Round in 2024
Wonder is a technology company that specializes in gaming and food delivery services. It offers an all-in-one gaming platform for Android mobile devices, enabling users to play, stream, and share games across various devices. Additionally, Wonder operates a food delivery service using trucks that function as mobile restaurants. Customers order food through a mobile app, and the Wonder trucks drive to a location near the user's home to prepare and deliver fresh meals on-site.

Lily AI

Series B in 2024
Lily AI is an innovative e-commerce product discovery platform based in Mountain View, California, that focuses on enhancing the sales performance of brands and retailers. The company specializes in integrating customer-centric product attributes into various facets of the e-commerce ecosystem, including site search engines and recommendation systems. By aligning brand messaging with customer intent, Lily AI improves on-site search, personalized product discovery, and demand prediction. This approach enables retailers, particularly in the fashion, home, and beauty sectors, to achieve significant increases in traffic, conversion rates, revenue, and brand loyalty.

Together AI

Series A in 2024
Together is a technology services platform that offers a decentralized cloud specifically for artificial intelligence development. The company focuses on constructing open-source generative AI models and infrastructure, providing tools and resources that enable developers and researchers to train, refine, and deploy these models efficiently. Together's platform emphasizes accessibility and user-friendliness, allowing organizations of various sizes to leverage and enhance AI capabilities. By contributing innovative open-source research, models, and datasets, Together plays a significant role in advancing the field of AI and fostering collaborative development efforts.

Regulus Therapeutics

Post in 2024
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of microRNA-targeted therapies for various diseases. Founded in 2007 and headquartered in San Diego, California, the company focuses on innovative treatments for conditions such as kidney diseases and viral infections. Its lead product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, and RGLS4326, an anti-miR targeting miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. Additionally, Regulus is advancing a pipeline of preclinical drug candidates, including RGLS5579 to inhibit miR-10b, as well as programs aimed at treating Hepatitis B virus and Non-Alcoholic Steatohepatitis. The company's work leverages the recent scientific advancements in microRNA research, which play a crucial role in regulating gene expression.

Propense.ai

Seed Round in 2024
Propense.ai is a SaaS platform that utilizes AI technology to help businesses identify new revenue streams. By employing a predictive sales intelligence model, it analyzes historical and market data to uncover hidden revenue opportunities. The platform offers real-time access to cross-selling scores, precise forecasting metrics, and predictive growth intelligence, which empowers firms to understand what products or services to sell to their clients next. By surfacing high-potential market opportunities and addressing revenue leakage, Propense.ai enables business leadership and professionals to enhance client service, gain strategic insights, and ultimately increase overall revenue.

Glacier

Venture Round in 2024
Glacier, founded in 2019 and headquartered in San Francisco, California, specializes in the development of advanced recycling robots. The company has created the first affordable, high-performing, and space-efficient AI-enabled robots designed to transform the operations of recycling facilities. By utilizing artificial intelligence-powered sensors and robotics, Glacier's technology automates the sorting of recyclable materials, allowing facilities to enhance operational efficiency, improve sorting accuracy, and increase overall profitability. Through its innovative approach, Glacier aims to revolutionize the recycling industry and promote more effective waste management practices.

Inkitt

Series C in 2024
Inkitt GmbH is a Berlin-based company founded in 2013 that operates an online community for writers and readers. It provides a platform for authors to share, review, and promote their stories across various genres, including horror, fantasy, romance, sci-fi, and more. Inkitt utilizes a unique data-driven approach to publishing, leveraging crowd wisdom and an algorithm called ReadRank to identify potential bestsellers. The platform allows authors to post their works-in-progress and receive feedback from readers, who can access these manuscripts for free for a limited time. Inkitt also encompasses interconnected applications, including Galatea, which sells optimized stories chapter by chapter, and GalateaTV, which adapts successful e-books into short-form television series. This ecosystem aims to create engaging storytelling experiences across multiple media, with a focus on hyper-personalization through AI to tailor content to individual preferences.

Genmo

Venture Round in 2024
Genmo is a technology company that develops an artificial intelligence platform for creative content generation. Its platform enables users to create high-quality videos, images, and 3D models using intuitive text and image prompts, leveraging advanced natural language processing technology. This allows video creators to generate custom visual media and produce cinematic video content with the assistance of AI.

Metronome

Series B in 2024
Metronome is a billing infrastructure company focused on supporting software companies in launching, iterating, and scaling their usage-based business models. The company offers metering and data mediation software that enhances billing capabilities, ensuring a robust data infrastructure and real-time architecture tailored for usage-based billing. Metronome emphasizes rapid deployment, flexibility, and user-friendliness, reducing the engineering demands typically associated with billing systems. This enables business and product teams to manage revenue and pricing effectively. Following initial platform integration, teams can quickly introduce new products and pricing options, streamline revenue workflows, and grant customers immediate access to their spending insights.

Comanche Biopharma

Series B in 2024
Comanche Biopharma is a biopharmaceutical company focused on developing an investigational siRNA medicine aimed at addressing preterm preeclampsia, a serious pregnancy complication. The company is committed to creating safe and effective treatment options that are both evidence-based and affordable, ensuring that all women and their infants can access necessary therapies for life-threatening conditions during pregnancy. By targeting the root causes of preeclampsia, Comanche Biopharma aspires to provide sustainable solutions that improve maternal and fetal health outcomes.

Second Front

Venture Round in 2024
Second Front Systems, Inc. is a technology company focused on enhancing government access to innovative, commercially developed technologies for national security applications. Founded in 2014 and headquartered in Arlington, Virginia, the company specializes in software solutions that facilitate the identification, assessment, and deployment of venture capital-backed technologies. Its primary product, Atlas Fulcrum, is a platform designed to streamline the discovery and engagement process for government users seeking advanced commercial technologies. Additionally, Second Front offers program management and system integration services to ensure the effective delivery of these technologies to military personnel. The company also operates the High Technology Council, an enterprise consortium that brings together key stakeholders to promote the application of venture-backed innovations in government-funded national security missions. With additional offices in Washington, D.C., and San Francisco, Second Front is positioned to transform how government entities access and utilize cutting-edge technology.

Perplexity

Series B in 2024
Perplexity is an artificial intelligence-based search engine platform that combines large language models with traditional search engines. It leverages natural language processing and generative AI technologies to deliver conversational responses to user queries, aiming to enhance the search experience beyond standard results. The platform is designed to facilitate the development of safe and beneficial artificial general intelligence, offering an open-source environment accessible to the public. This allows clients to acquire skills and knowledge in software development, positioning Perplexity as a bridge between conventional search capabilities and advanced AI-driven assistance.

VAST Data

Series E in 2023
VAST Data, Inc. is a technology company that specializes in developing innovative data storage solutions. Headquartered in New York, with additional offices in San Jose, California, the company offers a universal storage platform that utilizes Intel’s Optane SSDs as a cache for data stored on quad-level cell (QLC) SSDs. VAST Data's solutions cater to various sectors, including animation and visual effects, deep learning, life sciences, media and broadcasting, and enterprise backup and recovery. The platform is designed to enhance productivity, streamline data management, and accelerate time-to-insight for workload-intensive applications, making it particularly valuable for AI-driven organizations. Founded in 2016, VAST Data has rapidly established itself as a leading player in the data infrastructure market.

Gravel

Venture Round in 2023
Developer of a construction workforce platform intended to optimize the workforce. The company's technology makes it simple to find qualified and trustworthy construction workers by democratizing access to blue-collar workforces without boundaries, it also provides residential repair & maintenance services and building materials online, enabling clients to solve quality labor shortages and deal with construction-related problems.

Second Front

Series B in 2023
Second Front Systems, Inc. is a technology company focused on enhancing government access to innovative, commercially developed technologies for national security applications. Founded in 2014 and headquartered in Arlington, Virginia, the company specializes in software solutions that facilitate the identification, assessment, and deployment of venture capital-backed technologies. Its primary product, Atlas Fulcrum, is a platform designed to streamline the discovery and engagement process for government users seeking advanced commercial technologies. Additionally, Second Front offers program management and system integration services to ensure the effective delivery of these technologies to military personnel. The company also operates the High Technology Council, an enterprise consortium that brings together key stakeholders to promote the application of venture-backed innovations in government-funded national security missions. With additional offices in Washington, D.C., and San Francisco, Second Front is positioned to transform how government entities access and utilize cutting-edge technology.

Martian

Seed Round in 2023
Martian is a developer of an artificial intelligence platform focused on enhancing model performance through improved interpretability. The company specializes in creating alternatives to the traditional transformer architecture, aiming to provide clients with more effective AI solutions. By automatically routing every prompt to the most suitable large language model, Martian enhances the efficiency and outcomes of AI applications. Its innovative approach to AI alignment seeks to deliver better models that can be tailored to meet specific client needs, ultimately driving advancements in product performance.

Ozone

Seed Round in 2023
Ozone is an innovative company that has developed an AI-powered video editing platform designed to enhance the creative process for users. By enabling remote collaboration, Ozone allows creative producers to edit high-definition footage seamlessly without the need for bulky hardware or slow processing times. The platform supports features such as instant video mockup creation, effortless color correction, and real-time previews of edits, making it a valuable tool for those in the creative industry. Ozone's focus is on providing a user-friendly experience that empowers creatives to extend their capabilities and streamline their workflows, all within a cloud-based environment that prioritizes speed and accessibility.

LXA

Seed Round in 2023
LXA is a fintech venture focused on reimagining Asia's mortgage ecosystem. Geared towards matching institutional capital pools and residential mortgage borrowers, this platform aims to utilize end-to-end technology to streamline the entire mortgage lifecycle, from loan origination and borrower processing to loan servicing. LXA was founded in early 2023 by seasoned executives across the asset management, insurance, mortgage, and technology industries to bridge the gap between mortgage assets and institutional capital in Asia, beginning with Singapore. Combining best practices from North American and European markets with a proprietary technology platform focused on digital credit decisioning and intelligent workflow orchestration, LXA provides the first of its kind solution to address strong demand from Asian insurers and borrowers for differentiated mortgage products.

Transfix

Series F in 2023
Transfix, Inc. is a trucking brokerage firm based in New York, specializing in connecting shippers with carriers for freight transportation across the United States. Founded in 2010, the company has developed an advanced online freight management platform that utilizes AI-driven algorithms to optimize freight matching and enhance supply chain visibility. Transfix offers real-time shipment tracking, alerts, and insights on carrier performance, ensuring efficient and reliable transportation solutions. The company serves a diverse range of industries, including retail, food, beverage, and manufacturing, focusing on creating a sustainable freight ecosystem while minimizing empty miles and improving operational efficiency. Through its Intelligent Freight Platform, Transfix aims to revolutionize supply chain performance and support organizations in achieving their logistics goals.

Waymark

Venture Round in 2023
Waymark is a company focused on enhancing the accessibility and quality of healthcare for individuals who receive Medicaid. It offers community-based healthcare services aimed at improving patient outcomes. The company provides health plans, insulin education, training, and employment opportunities for community-based care teams. Additionally, Waymark partners with primary care providers to help Medicaid beneficiaries manage their health effectively.

Mojo Vision

Series A in 2023
Mojo Vision Inc. is a technology company based in Saratoga, California, founded in 2015. The company specializes in the development of augmented reality solutions, focusing on high-performance micro-LED display technology. Mojo Vision has created the world's smallest and densest dynamic display for smart contact lenses, which are designed to provide users with timely information seamlessly and hands-free, without the distractions associated with traditional mobile devices. The company is also engaged in a joint development agreement with Menicon Co., Ltd. to explore smart contact lens products, further enhancing its innovative offerings. By combining advanced display and semiconductor expertise with proprietary quantum-dot technology, Mojo Vision aims to revolutionize the display industry, addressing diverse applications across consumer, enterprise, and government sectors.

Pair Eyewear

Series C in 2023
Pair Eyewear, Inc. is a New York-based company that specializes in customizable eyeglasses for children. Founded in 2017 by Nathan Kondamuri and Sophia Edelstein, the company offers a unique approach to eyewear by providing base frames and interchangeable top frames that allow kids to express their personal style and interests. By combining functionality with creativity, Pair Eyewear transforms glasses from mere medical devices into a fun and engaging accessory for children. The company's direct-to-consumer model leverages an e-commerce platform, making the purchasing process convenient for parents while enhancing the overall experience for young wearers. Pair Eyewear is committed to offering quality, affordable glasses that are both stylish and practical, featuring hand-polished frames and shatterproof polycarbonate lenses.

Pulumi

Series C in 2023
Pulumi Corporation is a Seattle-based cloud engineering company that specializes in an infrastructure-as-code platform for developing cloud software. Founded in 2017, Pulumi provides an open-source software development kit (SDK) that enables developers and DevOps teams to create, deploy, and manage cloud applications and infrastructure using familiar programming languages. The platform supports various cloud environments, including public, private, and hybrid clouds, facilitating the delivery of modern applications through a collaborative approach. Pulumi's tools and frameworks cater to a wide range of use cases, from serverless functions to containerized applications, allowing enterprises to effectively manage their cloud services and streamline their cloud engineering processes.

Meeno

Seed Round in 2023
Meeno is a developer of an AI-driven relationship mentoring platform designed for young adults, particularly targeting Gen Z. The platform offers personalized coaching exercises aimed at improving close relationships and enhancing overall well-being. By utilizing artificial intelligence, Meeno provides tailored feedback and guidance on various relationship aspects, helping users strengthen their social connections. This focused approach positions Meeno as a vertical AI product within the realm of personal development and relationship enhancement.

Rocket.Chat

Series A in 2023
Rocket.Chat Holdings, Ltd., established in 2015, specializes in developing and operating an open-source web chat platform. The company offers a comprehensive suite of features, including video conferencing, helpdesk chat, file sharing, and screen sharing, along with API and native mobile applications. Rocket.Chat also provides white labeling, integrations, and hosting services. With over 500,000 servers installed and 12 million users worldwide, the platform facilitates internal and external communication within a secure environment. Users can run Rocket.Chat on-premises or on the cloud, tailoring the platform with features like individual and group communication, video conferencing, and integration with various external communications platforms. The company's long-term vision is to replace email with a real-time, federated communications platform and foster a marketplace for app-building and services.

Modyfi

Seed Round in 2023
Modyfi is an innovative image editing platform that enhances creativity and collaboration in the design process. Utilizing artificial intelligence, Modyfi offers real-time, multi-user editing tools that facilitate seamless collaboration among designers. The platform centralizes projects and resources, allowing users to share progress, gather feedback, and engage in commenting and markups. Additionally, Modyfi incorporates video chat features, making it easier for teams to communicate effectively during the photo-editing process. By streamlining workflows, Modyfi empowers users to integrate image editing into their projects more efficiently.

Fizz

Series B in 2023
Fizz is an authorized platform designed to enhance community social structures, particularly within institutions. It develops online social media software that facilitates communication and the sharing of ideas, events, and experiences among users. The platform allows individuals to post secret confessions and ask questions within a closed community, promoting social interaction while maintaining anonymity. By leveraging these features, Fizz aims to foster a more connected and engaged community environment.

NeueHealth

Post in 2023
NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Functional Finance

Seed Round in 2023
Functional Finance is a fintech platform designed to enhance the operational efficiency of the insurance industry. The company provides a comprehensive software solution that enables insurance operators to manage various aspects of money transfer, including billing, invoicing, payment collection, statement generation, and real-time automatic reconciliation for every invoice and policy. This platform allows insurance companies to unify and automate their financial operations and workflows without needing to replace their existing infrastructure.

Nexo Therapeutics

Series A in 2023
Nexo Therapeutics is a small molecule oncology company focused on discovering and developing innovative drugs for cancer patients who have limited therapeutic options. The company utilizes a unique platform that integrates covalent ligand discovery and chemical biology, allowing it to advance small-molecule therapies aimed at challenging and previously intractable cancer targets. By unlocking a pipeline of novel oncology treatments, Nexo Therapeutics seeks to provide medical professionals with new and effective options to improve patient outcomes in the fight against cancer.

Gossamer Bio

Post in 2023
Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

Embrace

Venture Round in 2023
Embrace is a developer of a unified observability and error monitoring platform that enables engineers to effectively manage the complexities of mobile applications. The platform provides comprehensive insights by allowing users to access detailed behavioral and technical context, helping teams identify and prioritize issues instantly. Embrace empowers engineers to track user sessions, monitor activities, and analyze data related to app performance, including every view, tap, network request, and memory usage. By eliminating fragmented solutions and guesswork, Embrace enhances the ability of companies to resolve issues quickly and optimize mobile experiences, ultimately fostering the development of better and more impactful mobile applications.

SpyGlass Pharma

Series C in 2023
SpyGlass Pharma specializes in developing innovative treatments for chronic ophthalmic diseases through advanced technology. The company creates ophthalmic devices and a drug delivery platform aimed at enhancing vision and eye care for patients. Its products address unmet needs in areas such as cataracts, lens replacement, and surgical procedures. The drug delivery platform is designed to be implanted alongside intraocular lenses during standard cataract surgeries, allowing for the provision of multi-year therapy to treat chronic eye conditions. This approach not only facilitates effective treatment but also aims to make quality eye care more accessible and affordable for patients.

Tagworks Pharmaceuticals

Series A in 2023
Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

Djust

Series A in 2023
Djust is a company that specializes in providing a cloud-based B2B platform aimed at accelerating the launch of e-commerce and e-procurement solutions for businesses. The platform integrates digital showrooms, an e-commerce marketplace, and customer relationship management (CRM) systems into a single product, streamlining the process for clients to establish and enhance their online business presence. By offering this comprehensive solution, Djust simplifies the complexities of setting up digital commerce for businesses, making it easier for them to engage in online transactions and expand their operations.

Granica

Series A in 2023
Granica is a company that specializes in enhancing the efficiency and safety of artificial intelligence applications through its AI Data Readiness Platform. This platform assists data engineers and leaders in creating AI-ready data, which is crucial for optimizing machine learning models and analytics. By improving the efficiency of tabular and natural language processing training data, Granica significantly reduces storage costs and enhances query performance. The company focuses on mitigating risks associated with sensitive data leakage and harmful content, thereby ensuring privacy and safety in AI inputs and outputs. Granica curates and refines training datasets to select impactful samples, ultimately boosting the performance and reliability of AI models. Targeting enterprises in data-intensive sectors such as financial services, retail, geo-spatial intelligence, and autonomous vehicles, Granica enables clients to leverage AI more effectively, enhancing trust and improving business outcomes.

Instabase

Series C in 2023
Instabase, Inc. is a technology company based in San Francisco, California, founded in 2015. It specializes in developing a platform that automates document processing workflows and analyzes unstructured data. The platform integrates various capabilities, including optical character recognition, data classification and extraction, and natural language processing, allowing organizations across sectors such as insurance, finance, and healthcare to streamline operations and improve decision-making. Additionally, Instabase provides a developer kit that enables the creation of customized business applications, helping institutions embed artificial intelligence into their systems and processes. Through its innovative solutions, Instabase aims to address significant business challenges and facilitate transformational outcomes for its clients.

Strive Health

Series C in 2023
Strive Health, LLC is a company focused on providing comprehensive solutions for chronic kidney disease. Founded in 2018 and based in Denver, Colorado, Strive Health operates dialysis centers and employs advanced predictive analytics to enhance patient care. The company offers a high-touch, technology-enabled clinical model that supports patients throughout their healthcare journey, from primary care engagement to dialysis treatment. By utilizing comparative and predictive data, Strive Health aims to identify at-risk patients and transform the management of kidney disease, promoting earlier intervention and increasing the adoption of home dialysis. This innovative approach not only improves patient outcomes but also seeks to reduce inpatient utilization, ultimately enhancing the overall experience for individuals dealing with chronic kidney conditions.

Sundeck

Seed Round in 2023
Sundeck is a data infrastructure and analytics company based in Santa Clara, California, founded by Jacques Nadeau in 2022. The company specializes in enhancing and customizing the behavior of Snowflake queries, providing a platform that allows for warehouse optimization, adaptive routing, and granular cost control. Sundeck's innovative query engineering solutions enable data engineers to tackle complex challenges with a straightforward and configurable approach. The platform supports pre- and post-hook SQL execution across various business intelligence, notebook, and AI tools, empowering users to unleash creativity while maintaining control over their data operations.

Union.ai

Series A in 2023
Union.ai is a Kubernetes-native workflow orchestration platform for data and machine learning at scale. Union.ai provides software users with the tools they need to move their ideas from concept to high-quality production. Union's aim is to organize the numerous processes required to train and grow the most sophisticated and dynamic machine learning and data products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.